PEGylated Platinum Nanoparticles: A Comprehensive Study of Their Analgesic and Anti-Inflammatory Effects

Title

PEGylated Platinum Nanoparticles: A Comprehensive Study of Their Analgesic and Anti-Inflammatory Effects

Creator

Waliaveettil F.A.; Jose J.; Anila E.I.

Description

Pain and inflammation are common symptoms of a majority of the diseases. Chronic pain and inflammation, as well as related dreadful disorders, remain difficult to control due to a lack of safe and effective medications. In this work, biocompatible platinum nanoparticles with significant analgesic and anti-inflammatory action were synthesized through a wet chemical method using polyethylene glycol-400 as a capping agent and sodium borohydride as a reducing agent. The average particle size of these Pt nanospheres was determined to be 3.26 nm using TEM analysis, and X-ray diffraction confirmed their face-centered cubic crystalline structure. Fourier transform infrared and UV-visible spectroscopy confirm that Pt-NPs are coated with the PEG-400 molecule. The significantly negative zeta potential value (?26.8 mV) indicates the stability of the produced nanoparticles. In vitro cytotoxicity studies on normal cell lines show nontoxic behavior with over 96% cell viability at 100 ?g/mL of the test sample. In vitro assays of inhibition of protein denaturation and DPPH free radical scavenging elucidated the anti-inflammatory and antioxidant properties of PEGylated Pt NPs with promising EC50 values 57.99 and 9.324 ?g/mL, respectively. In vivo animal trials confirmed that PEG-capped Pt-NPs are more effective than conventional medicines. The in vivo hot plate assay for the analgesic study shows a maximum response time of 14.5 1.22 s (92.54% analgesia) at a dosage of 50 mg/kg and 13.8 0.71 s (86.05% analgesia) at a dosage of 25 mg/kg after 180 and 240 min of administration, respectively. In the rat paw edema model for anti-inflammatory activity, the PEG-capped Pt NPs exhibit significant inhibitory action, with the maximum percentage of edema inhibition at a dosage of 50 mg/kg identical to that of the aspirin-based standard medication administered at a higher dosage of 100 mg/kg, resulting in 42% inhibition, suggesting a versatile solution for inflammation and persistent pain. 2025 American Chemical Society.

Source

ACS Applied Bio Materials, Vol-8, No. 1, pp. 628-641.

Date

2025-01-01

Publisher

American Chemical Society

Subject

Analgesic property; Anti-inflammatory Property; Cytotoxicity; DPPH assay; Platinum nanoparticles; Polyethylene glycol

Coverage

Waliaveettil F.A., Department of Physics and Electronics, Christ University, Karnataka, Bengaluru, 560029, India; Jose J., Division of Microbiology, Department of Biosciences, Rajagiri College of Social Sciences (Autonomous), Kerala, Cochin, 683104, India; Anila E.I., Department of Physics and Electronics, Christ University, Karnataka, Bengaluru, 560029, India

Rights

Restricted Access

Relation

ISSN: 25766422; PubMed ID: 39746938

Format

Online

Language

English

Type

Article

Identifier

https://doi.org/10.1021/acsabm.4c01498

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85215382018&doi=10.1021%2facsabm.4c01498&partnerID=40&md5=4de439a70d17da2b455df9c022dd0bff